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Abstract 
Cardiovascular diseases (CVDs) are the leading cause of death in the world. CVDs are 
typically due to atherosclerosis, a build-up of plaque that results in arterial blockage. Currently, 
the most common solution is balloon angioplasty surgery, which is only a temporary solution 
because even though the arteries are widened again, revascularization results in arterial injury. 
This injury triggers the body’s natural response: inflammation through the proliferation and 
migration of smooth muscle cells (SMC), narrowing the artery again—a process called 
restenosis—requiring further surgeries. Cinnamic aldehyde (CA) has been shown to inhibit SMC 
proliferation and migration by activating the Nrf2-Keap1 pathway, but it has a systemic effect. 
We aim to form a cell-mediated targeted drug delivery system using macrophages and micelle 
nanoparticles to transport CA to activate the Nrf2-Keap1 pathway and prevent restenosis. As a 
result of sparse data, the micelles were first characterized by dynamic light scattering (DLS) and 
nanoparticle tracking analysis (NTA) to determine size (232.7 nm in diameter) to ensure the 
nanoparticles were large enough to be taken up by macrophages. Then, THP-1 macrophage 
uptake of rhodamine labeled micelles was studied by live-cell microscopy. Through Western 
Blot and 3-(4,5-Dimethylthiazol-2-Yl)- 2,5-Diphenyltetrazolium Bromide (MTT) assays, CA-
loaded nanoparticles were found to activate the Nrf2-Keap1 pathway and inhibit vascular SMC 
proliferation, respectively. These results establish the groundwork for future investigation into 







Responsible for over thirty percent of deaths in the world, cardiovascular diseases 
(CVDs) pose a serious threat.7 Atherosclerosis is the underlying cause of most CVDs. 
Atherosclerosis is the accumulation of fat deposits in the arteries, resulting in plaque build-up 
and blockage of blood flow, which can lead to coronary heart disease, strokes, and other heart 
and blood vessel disorders. Current revascularization methods, including balloon angioplasty, 
stenting, and bypass grafting, are only effective temporarily: even though surgeries widen 
arteries, the body registers any type of intervention as injury and responds by inflaming the 
affected site through the proliferation and migration of vascular smooth muscle cells (VSMCs). 
Driven by cell proliferation, the arterial wall thickens, and the artery narrows again in a process 
called restenosis, warranting further surgeries. These surgeries are expensive, and as a 
consequence, resources are wasted.  Researchers are investigating ways to prevent restenosis by 
impeding VSMC proliferation and migration. As VSMC proliferation and migration is mediated 
by increased production of reactive oxygen species (ROS) in CVDs, we explored an avenue of 
altering ROS levels. 
One approach to reduce VSMC proliferation by altering the levels of ROS is the Nrf2-
Keap1 pathway. Keap1 regulates the activity of Nrf2 (NF-E2-related factor 2)—an inducible 
transcription factor. In normal conditions, Nrf2 is degraded, but under oxidative or electrophilic 
stress, Nrf2 is not degraded and translocates to the nucleus. This allows Nrf2 to promote the 
expression of antioxidant enzymes.6 The Bahnson Research Group has identified cinnamic 
aldehyde (CA), the hydrophobic compound responsible for the unique flavor and scent of 
cinnamon, as capable of activating Nrf2 by its electrophilic nature and inhibiting VSMC 
proliferation and migration.1 By activating the Nrf2-Keap1 pathway, CA intensifies antioxidant 
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production and effectively reduces the proliferation and migration of VSMCs. However, CA has 
a systemic effect, reducing VSMC proliferation and migration throughout the body. Therefore, 
we aim to develop a cell-mediated targeted delivery system that will activate the Nrf2-Keap1 
pathway and prevent restenosis.  
Since part of the body’s natural arterial injury response involves the migration of 
macrophages to the site of injury, macrophages can act as transport vehicles.2,3,8 We propose 
packaging CA in pluronic micelles (PMs) to increase macrophage uptake, and use the 
macrophages to deliver CA to VSMCs. PMs are tri-block copolymers, with two hydrophilic 
blocks surrounding a hydrophobic block. The lengths of these polymers vary among pluronics, 
resulting in differing hydrophobicities. At concentrations above the critical micellar 
concentration (CMC), PMs are in a dynamic equilibrium between assembling into micelles and 
disassembling into separate molecules. Because of this dynamic equilibrium and CA’s 
hydrophobicity, we know CA will be encapsulated when the PMs form and released when they 
disassemble. Therefore, we hypothesize that CA-encapsulated PMs will be taken up by 
macrophages and then delivered and released to VSMCs to inhibit proliferation locally. To test 
this hypothesis, we characterized pluronics, observed THP-1 macrophage uptake, and treated 
Sprague Dawley cells in vitro to confirm inhibition of VSMC proliferation and Nrf2-Keap1 
pathway activation.  
Methods 
Cell Culture Vascular smooth muscle cells (VSMCs) from Sprague Dawley rats were stored at 
concentrations of 1x106 cells/mL in cryovials in 90% complete media (DMEM and Ham’s F-12 
in a 1:1 ratio with 10% FBS, 1% streptomycin/penicillin, and 0.8% L-glutamine) and 10% 
DMSO in liquid nitrogen tanks. 1x106 cells were thawed into a 175 cm2 Corning® Cell Culture 
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Flasks with fresh complete media to adhere and grow until reaching 80% confluency before use. 
Once a week, when cells reached 80% confluency, the VSMCs were passed into new flasks at a 
density of 1x106 cells/flask in complete media until the tenth passage, at which point they were 
discarded. 
         THP-1 monocytes in RPMI media with 10% FBS and 1% streptomycin/penicillin 
differentiated after being in the presence of 162 nM PMA for 48 hours. Differentiation was 
confirmed by assessment of cell morphology by light microscopy and then THP-1 macrophages 
were stored in 75 cm2 Corning® Cell Culture Flasks. 
Pluronic Micelles Solid pluronics F-127 (75.5% ethylene oxide and 24.5% propylene oxide, 
12,600 g/mol) and P-84 (46.9% ethylene oxide and 53.1% propylene oxide, 4,200 g/mol) were 
dissolved in distilled water to form 20% mass by volume solutions, and solid pluronic L-101 
(23.4% ethylene oxide and 76.6% propylene oxide, 3,800 g/mol) was dissolved in distilled water 
to form a 15% mass by volume solution. The solutions were stored in 4ºC until use. 
Critical Micellar Concentration (CMC) Determination A BioTek® Cytation 5 Cell Imaging 
Multi-Mode Reader was used to determine fluorescence emission maxima of 300 nM Nile Red 
solutions from wavelengths 575 nm to 700 nm with varying concentrations of pluronic from 0% 
to 20% mass by volume. These measurements were taken in triplicates. The average differences 
and standard deviations in peak fluorescence between the pure solvent and each of the other 
solutions containing pluronic in greater than 0% mass by volume were calculated and graphed 
with the OriginLab® software OriginPro 2016 to identify the concentration at which micelles 
formed for each pluronic. 
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Dynamic Light Scattering (DLS) The Malvern Zetasizer Nano series program quantified the 
sizes and level of dispersion of micelles diluted to 0.025% mass by volume in distilled water and 
PBS in glass Malvern cuvettes. 
Nanoparticle Tracking Analysis (NTA) A Nanosight NTA was primed with filtered, distilled 
water for quantifying the size and size distribution of nanoparticles (PMs in this instance) diluted 
to 0.025% in distilled water, and then primed with filtered PBS to quantify the size and level of 
dispersion of micelle sizes diluted 0.025% mass by volume in PBS.  
Fluorescent Labeling of PMs Pluronics were labeled with 5.25 µM rhodamine-123 (Sigma 
Cat#83701) to track PMs via fluorescence microscopy using a GFP filter (ex=450-480nm, 
em=500-550nm; recommended ex=488nm, em=515-575nm). For some experiments, THP-1 
macrophages were grown on a cover slip, labeled with 0.05 µM, 0.1 µM, and 0.5 µM DiI, and 
incubated at 37ºC for 18 hours. After incubation, the coverslips were dipped in 6 mM DAPI to 
label the macrophage nuclei. 
Macrophage Micelle Uptake Bright-field and fluorescence microscopy was accomplished with 
the BioTek® Cytation 5 Cell Imaging Multi-Mode Reader to observe the uptake of 5.25 µM 
rhodamine-123-labeled micelles by THP-1 macrophages over the course of 4 hours. Macrophage 
uptake was compared to uptake of rhodamine-123 without micelles, along with macrophage 
uptake of CA-encapsulated micelles. Images of fluorescently labeled pluronics and macrophages 
were also taken with a Zeiss microscope using a 60X objective to confirm macrophage uptake of 
rhodamine-123-labeled PMs, using DAPI, Cy3, and Cy5 filters to detect. 
MTT Sprague Dawley VSMC were seeded onto a Falcon® 96-Well Plate at a density of 5x103 
cells/well. VSMC were treated with varying concentrations of just CA (0 µM to 1.6 mM), just 
pluronic L-101 (from 0.01% to 10% mass by volume), and finally, CA encapsulated in a constant 
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concentration of 0.05% pluronic L-101 (0 µM to 800 µM) in replicates of eight. After treatment, 
a solution of 0.4 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT 
dye) and VSMC complete media was administered in equal concentrations to all conditions and 
the cells were incubated for four hours before the dye solution was dumped and left to dry. After 
24 hours, DMSO was added to the dry wells and the BioTek® Cytation 5 Cell Imaging Multi-
Mode Reader indirectly quantified the concentration of living cells based on absorbance values. 
The experiment was repeated three times. 
Western Blot Sprague Dawley VSMC were plated at 1.5x106 cells in a 10 cm petri dish and 
treated with four conditions in triplicate for four hours: VSMC complete media, 0.05% pluronic 
L-101, 100 µM CA, and 0.05% pluronic L-101 with 100 µM CA. The dishes were rinsed twice 
with HBSS and placed in ice for 10 minutes. The cells were collected into separate centrifuge 
tubes using a cell lifter. The cells were centrifuged for 5 minutes at 1200 rpm. The HBSS was 
replaced with 1X Lysis Buffer. Heat-denatured proteins were added in equal concentrations 
(quantified by using PierceTM BCA Protein Assay Kit and protocol) to the lanes of a 
nitrocellulose gel with SDS and gel electrophoresis was run for 1 hour at a constant voltage of 
180 V in 1X Running Buffer. The proteins were transferred to a PVDF membrane for 2 hours at 
a constant current of 250 mA. The membrane was submerged in blocking buffer overnight, 
rinsed with PBS-T, and blotted with primary antibodies targeting Nrf2, HO-1, and ß-actin, and 
secondary fluorescent antibodies. The membrane was imaged with LI-COR® Odyssey Imaging. 
Results 
Micelle Formation 
         Pluronics are tri-block co-polymers with hydrophobic blocks at both ends of hydrophilic 
blocks. When dissolved to form an aqueous solution, the block co-polymer seeks to minimize 
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interactions between the hydrophobic block and water. Therefore, at high enough concentrations, 
the block co-polymers naturally assemble to form micelles, in which the hydrophobic polymers 
are internalized and separated from water by the hydrophilic polymers. These micelles are in 
dynamic equilibrium between micelle nanoparticles and dissociated free polymers. The lowest 
concentration at which the micelles form is called the critical micelle concentration (CMC). To 
determine the CMCs of each pluronic, a Nile Red fluorescence assay was conducted, in which 
the fluorescent emission maxima of Nile Red depended on the polarity of the environment 
experienced. In polar environments, Nile Red maximally fluoresces red, but in apolar 
environments, Nile Red fluorescent emission maxima shift toward lower wavelengths, known as 
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Figure 1. Determination of CMC. (A) Mechanism of Nile Red fluorescence to identify CMC.  (B) Peak 
fluorescent intensity of pure solvent against different PM solutions of varying concentrations with Nile 
Red was measured.  (C) Blue shifts between the pure solvent and each concentration of the three PMs 	
identify varying or high CMCs for both F-127 and P-84, and a low CMC of 0.01% for L-101 (n = 3). 
Error bars represent standard deviation.	 
 
different PMs (F-127, P-84, and L-101) in water and PBS were measured. These intensities were 
used to identify the CMCs through calculating the blue shift—the difference in peaks of 
fluorescence between a pure solvent and a solution of the solvent with pluronic (Fig 1a). The 
blue shift was similar for the dilutions at which micelles did not form, and then increased greatly 
to similar shifts for concentrations at which micelles did form, in which they encapsulated the 
fluorophore Nile Red and affected its maximal emission wavelength. Based on the 
concentrations of pluronic at which jumps in the blue shifts occurred, it was determined that the 
CMC was 8% in water and 4% in PBS for Pluronic F-127 (PF127), 8% in both water and PBS 
for Pluronic P-84 (PP84), and 0.01% in both water and PBS for Pluronic L-101 (PL101) (Fig 




















Figure 2. Characterization of P-
L101. (A) The size and level of 
dispersion was measured by DLS. 
(B) NTA also measured size and 
dispersity, in addition to the 





We used two methods to determine the size of Pluronic L-101 PMs. Dynamic Light 
Scattering (DLS) determined the average size (250.9 nm in diameter) and polydispersity (0.193) 
of a 0.025% filtered solution of PMs in water (Fig 2a). Nanoparticle Tracking Analysis (NTA) 
Figure 3. Rhodamine effectively labels P-L101 
PMs. The efficacy of rhodamine uptake by 
Pluronic L-101 4 hours after rhodamine 
treatment. 
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also measured the average size of a filtered 0.025% solution of PMs in water (158.1 nm in 
diameter) (Fig 2b). 
To label the Pluronic L-101 PMs, we examined the uptake the green fluorophore 
rhodamine-123 for future imaging experiments in which we needed to differentiate the PMs from 
cells. These PMs were very effective, as indicated by the contrast between the bright green 
fluorescent in the micelles and the dark background. (Fig 3). 
THP-1 Macrophage Uptake of PMs 
 The ability of PMA-induced THP-1 macrophages (Figure 4), to uptake PMs was assessed 
by manually imaging cells every 15 minutes for 4 hours. Three conditions were tested: 1) a 
rhodamine control to confirm that fluorescence does not enter the macrophage without the aid of 
a pluronic (Fig 5a), 2) the rhodamine-labeled PMs administered alone (Fig 5b), and 3) 
rhodamine-labeled PMs with 50µM of cinnamic aldehyde (Fig 5c). Images of the rhodamine 
control show that without the pluronic, macrophages do not uptake rhodamine since the 
macrophages do not fluoresce green after four hours (Fig 5a). Contrasting the pictures taken  




imaged with a 10X 
objective (A) before 
and (B) after 24 hours 





of the macrophages incubated with only rhodamine and the pictures taken of the macrophages 
incubated with rhodamine-123-labeled PMs and rhodamine-123-labeled PMs with cinnamic 
aldehyde, the macrophages fluoresce green after four hours. This indicates that the macrophages 
take no more than 4 hours to uptake the PMs, represented by the macrophages fluorescing green 
after four hours when PMs are present, but not fluorescing when PMs are absent (Fig 5b, c). Any 
green observed in the images taken immediately after treatment is due entirely to the green 
background filter and does not indicate macrophage uptake.  
Figure 5. THP-1 Macrophage Uptake of CA-PMs. Top panels show live imaging of THP-1 
macrophages immediately after treatment with rhodamine-123 alone, rhodamine-123-labeled PMs, or 
rhodamine-123-labeled CA-PMs, and the bottom panels show live imaging of THP-1 macrophages 4 
hours after treatment.  
Figure 6. Labeling THP-1 Macrophages with DiI. Macrophage uptake of fluorescent maximized with 
(a) 0.5 µM DiI after 24 hours, (b) 1 µM after 6 hours, and (c) 1 µM after 3 hours. 
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THP-1 Macrophage Labeling with DiI 
Differentiated THP-1 monocytes were incubated in duplicates with either 0.5 µM or 1.0 
µM fluorescent DiI for 24 hours (Fig 6a), 6 hours (Fig 6b), and 3 hours (Fig 6c). When incubated 
for 24 hours, the best uptake was of 0.5 µM DiI, but for the other two time points, 1.0 µM DiI 
yielded the best results. To confirm that the DiI observed was in fact taken up by macrophages, 
the macrophage nuclei were stained with DAPI prior to imaging. Having confirmed that 
macrophages could be labeled with DiI, macrophage uptake of DiI was further examined to 
determine if it was possible to label the macrophages with lower concentrations of DiI (0.1 and 
0.05 µM) at a longer incubation time (18 hours). We observed high levels of macrophage 
labeling with 0.05 µM DiI and 18 h incubation (Fig 6). Finally, we assessed the uptake of 
rhodamine-123-labeled Pluronic L-101 PMs and cinnamic aldehyde-encapsulated in Pluronic L-
101 PMs tagged with rhodamine by DiI-labeled macrophages. This double-staining technique 
would allow for future experiments where we will use two different cell types in co-culture. We 
confirmed the presence of rhodamine-123-labeled L101 PMs in DiI-labeled macrophages after 
18-hour incubation (Fig 7). 
 
 
Figure 7. Labeled THP-1 Macrophage uptake of labeled PMs. THP-1 Macrophages labeled with DiI 
for were incubated with rhodamine-labeled PMs and rhodamine-labeled CA-PMs for 24 hours and 
imaged with an epifluorescence microscope (63x objective lens). THP-1 macrophages taking up 
rhodamine-labeled PMs are visualized by DiI positive puncta (yellow). 
Free and Encapsulated CA Inhibits Cell Proliferation 
Control PMs CA-PMs 
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         MTT assays were run in triplicate to identify the individual effects of PMs and cinnamic 
aldehyde on Sprague Dawley rat aortic smooth muscle cells, and then the combined effects of 
these two treatments.  PMs alone had an EC50 of 0.12% mass by volume (Fig 8a), meaning that 
at this concentration, VSMCs experienced half-maximal toxic effects. Therefore, in order to 
form micelles for CA encapsulation, but also not cause more than half-maximal toxic effects, 
Pluronic L101 PMs can only be administered in concentrations between 0.01% and 0.12% mass 
by volume. In the trials testing different concentrations of just CA, the EC50 was found to be 
250 µM (Fig 8b), and to assess if encapsulation in PMs affects the CA EC50, an MTT assay was 
run with a constant concentration of PMs at 0.05% mass by volume and varying concentrations 
of CA. The PM concentration was chosen to be 0.05% because it was a concentration above the 
CMC but below the EC50, such that the micelles should not affect the VSMCs. From this assay, 
encapsulation of CA appears to cause a shift in the EC50 to 430 µM (Fig 8c). This could be due 
to the cells only being incubated with PMs containing CA for four hours and CA contained by 
the PMs was unable to inhibit cell proliferation. Therefore, CA release from the PMs would be 
necessary for CA to inhibit cell proliferation.  
Figure 8. Encapsulation of CA in PMs Increases its EC50 in VSMC. Cell viability at different 
concentrations of (a) Pluronic L-101, (b) cinnamic aldehyde, and (c) cinnamic aldehyde with a constant 





CA-Dependent Activation of the Nrf2 Pathway 
Activation of the Nrf2 pathway requires stabilization and accumulation of the Nrf2 
protein. Our lab has previously shown that CA is capable of activating the Nrf2 pathway in 
VSMC due to its electrophilic nature.1 For PMs to be an effective delivery vehicle for CA, we 
tested if encapsulated CA was capable of inducing Nrf2. VSMCs were treated with media, empty 
PMs, free CA (250 𝜇M), or CA-PMs (250 𝜇M CA in 0.05% PMs) for 8 hours to be used in 
Western blot assays performed in triplicates. Cells were collected and immunoblot for Nrf2 was 
performed. The Nrf2 pathway was activated only when CA was present (empty PMs alone did 
not activate the Nrf2 pathway), and even when encapsulated in PMs, CA was still found to 







Figure 9. Encapsulated CA Activates 
Nrf2. Western blot analysis of Nrf2 and 
β-actin protein production under the 
following conditions: complete VSMC 
media, 0.05% PMs, 250 𝜇M CA, and 
0.05% PMs with 250 𝜇M CA (left to 
right) for 8 hours. 
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Discussion and Conclusions 
         After determining the CMC of three pluronics (F127, P84, and L101), we selected to 
work with P-L101 because it had the lowest CMC. This will allow us to use lower concentrations 
of polymer and achieve encapsulation of our drug of interest, CA. There were no significant 
differences in CMC when the assay was performed in water or PBS. This pluronic, P-L101 
formed PMs, with a diameter of 232.7 nm and a polydispersity index of 0.188 based on DLS 
readings. NTA readings were smaller by an average of 75.1 nm, but it may have been due to the 
NTA analyzing noise from other particles, rather than just PMs. We successfully labeled the PMs 
with rhodamine-123 to allow for fluorescent imaging. Uptake experiments show that 
macrophages can take up the PMs as evidenced in Fig 4 and Fig 7, and that uptake is maximal 
within 4 hours. Based on the MTT assays, PMs do not inhibit VSMC proliferation at the CMC, 
which allows us to use them as delivery vehicles for CA. CA has been shown to also inhibit the 
proliferation of VSMCs1, skin cells9, and cancer cells, such as in the liver5 and colon4.  
Delivering CA in micelles was expected to change the EC50, with the original hypothesis 
that the EC50 was going to decrease. Unexpectedly, PMs caused an increase in the EC50 of 
cinnamic aldehyde by almost 200 µM. This may be explained by a slow release of CA from the 
micelles when they disassemble into dissociated polymers due to their dynamic equilibrium. 
More experiments are needed to determine the mechanism by which PMs increase the EC50 of 
CA in VSMC. We also found that encapsulation of CA in PMs did not ultimately inhibit CA’s 
ability to activate Nrf2 and that such activation was not due to the presence of the PMs based on 
the Western blot. We found that it took eight hours for CA in PMs to maximize Nrf2 protein 
production, while CA alone took four hours to maximize Nrf2 protein production, which 
supports the theory of slow CA release by PMs.  
 17 
 Together, these results indicate that PMs can be loaded with CA to be taken up by 
macrophages and that the released CA-encapsulated PMs will activate the Nrf2-Keap1 pathway, 
inhibiting the proliferation of VSMCs and therefore inflammation, thus preventing restenosis. 
There are limitations to the research conducted thus far that require further experimentation to 
confirm results. The MTT assays are an indirect measurement of cell viability, showing only the 
relative number of living VSMCs, but do not quantify the ratio of live VSMCs to dead VSMCs. 
Furthermore, a co-culture has yet to be conducted, so it is currently unknown if the macrophages 
can deliver the micelles to the VSMCs, and if they can, how the VSMCs are affected. Therefore, 
future directions include using the Muse® Cell Viability Assay to determine cell count of living 
and dead cells, in addition to forming, observing, and quantifying a co-culture of VSMCs, THP-1 
macrophages, and CA-encapsulated PMs. Visually showing the release by macrophages and 
uptake by VSMCs of CA-PMs would be a step towards making cardiovascular surgery a more 
permanent solution. 
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